West Pharmaceutical Services, Inc. – Consensus ‘buy’ rating and 1.5% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

West Pharmaceutical Services, Inc. which can be found using ticker (WST) have now 7 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 460 and 325 and has a mean target at $400.71. Given that the stocks previous close was at $394.60 this would indicate that there is a potential upside of 1.5%. There is a 50 day moving average of $389.49 and the 200 moving average now moves to $332.96. The market capitalization for the company is 29.00B. The current share price for the company is: 392.61 USD

The potential market cap would be $29,447,659,711 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 57.23, revenue per share of 38.52 and a 12.49% return on assets.

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search